{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:21:47Z","timestamp":1791850907375,"version":"4.3.4"},"reference-count":42,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1185\/03007995.2014.944973","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T11:32:41Z","timestamp":1405423961000},"page":"2317-2328","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":64,"title":["Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase"],"prefix":"10.1185","volume":"30","author":[{"given":"Annie","family":"Gu\u00e9rin","sequence":"first","affiliation":[{"name":"Analysis Group Inc.","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Ionescu-Ittu","sequence":"additional","affiliation":[{"name":"Analysis Group Inc.","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna","family":"Marynchenko","sequence":"additional","affiliation":[{"name":"Analysis Group Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Analysis Group Inc.","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hiscock","sequence":"additional","affiliation":[{"name":"Analysis Group Inc.","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Keir","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Qiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group Inc.","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S29132"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Hughes TP Saglio G Kantarjian HM et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-60","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Beaumont JL Magestro M Coombs J et al. Assessment of patient reported outcomes (PROs) from the ENESTnd trial with minimum follow-up of 36 cycles. In: 54th ASH Annual Meeting and Exposition. Atlanta GA: American Society of Hematology 2012:abstract 3166","DOI":"10.1182\/blood.V120.21.3166.3166"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S33380"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_3_3_11_1","unstructured":"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) Capsules. Washington DC: US Food and Drug Administration 2007:1-21. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022068lbl.pdf [Last accessed 4 September 2013]"},{"key":"e_1_3_3_12_1","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v4.2013. 2013:1-95. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf [Last accessed 6 June 2013]"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01258.x"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23180"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3782.3782"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"e_1_3_3_17_1","unstructured":"Novartis Pharmaceuticals. A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). ClinicalTrials.gov. 2007. Available at: http:\/\/clinicaltrial.gov\/ct2\/show\/NCT00471497?term=ENESTnd&rank=1 [Last accessed 29 January 2014]"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-423418"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2210"},{"key":"e_1_3_3_22_1","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware JE","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, Rhode Island: QualityMetric, Inc., 1993"},{"key":"e_1_3_3_23_1","volume-title":"The manual of the functional assessment of chronic illness therapy (FACIT) measurement system","author":"Cella D","year":"1997","unstructured":"Cella D. The manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Evanston, IL: Center on Outcomes, Research, and Education, Evanston Northwestern Healthcare and Northwestern University, 1997"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.10.011"},{"key":"e_1_3_3_26_1","volume-title":"How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1)","author":"Ware JE","year":"2002","unstructured":"Ware JE, Kosinski M, Turner-Bowker DM, et al. How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated, 2002"},{"key":"e_1_3_3_27_1","first-page":"693","article-title":"SF-36 health survey update","author":"Ware JE","year":"2004","unstructured":"Ware JE. SF-36 health survey update. The use of psychological testing for treatment planning and outcomes assessment 3 2004;693-718","journal-title":"The use of psychological testing for treatment planning and outcomes assessment 3"},{"key":"e_1_3_3_28_1","unstructured":"MedDRA Maintenance and Support Services International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Introductory Guide MedDRA Version 17.0. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2011:1-83. Available at: http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_17_0_english.pdf [Last accessed 29 January 2014]"},{"key":"e_1_3_3_29_1","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. 2013. Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm [Last accessed 19 November 2013]"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990715)18:13<1707::AID-SIM138>3.0.CO;2-H"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511790942"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00314-0"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199001000-00010"},{"key":"e_1_3_3_34_1","first-page":"269","article-title":"Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha","volume":"11","author":"Hong H","year":"2003","unstructured":"Hong H, Qiu J-Y, Lai Y-Y, et al. Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003;11:269-73","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369017"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1458-6"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.51"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.09.006"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.7052"},{"key":"e_1_3_3_40_1","first-page":"221","article-title":"Quality-of-Life assessment for routine oncology clinical practice","volume":"6","author":"Halyard MY","year":"2008","unstructured":"Halyard MY, Ferrans CE. Quality-of-Life assessment for routine oncology clinical practice. J Support Oncol 2008;6:221-9, 233","journal-title":"J Support Oncol"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.671"},{"key":"e_1_3_3_42_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) C for BE and R (CBER). Guidance for Industry: Non-Inferiority Clinical Trials \u2013 Draft Guidance. Rockville MD: US Department of Health and Human Services Food and Drug Administration 2010:1-66. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm [Last accessed 25 April 2014]"},{"key":"e_1_3_3_43_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials. Rockville MD: US Department of Health and Human Services Food and Drug Administration 2001:1-37. Available at: http:\/\/www.fda.gov\/cder\/guidance\/index.htm [Last accessed 25 April 2014]"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2014.944973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T17:26:50Z","timestamp":1770398810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2014.944973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1185\/03007995.2014.944973"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2014.944973","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}